Vazyme: Plans to establish a joint venture with Yimiao Shenzhou, holding 50% of the shares

Vazyme announced that the company recently signed a "Cell Therapy Cooperation Project Development Agreement" with Yimiao Shenzhou, intending to jointly establish a biopharmaceutical company with a registered capital of RMB 40 million, with both parties holding 50% of the shares. The joint venture will carry out investment cooperation projects in the field of cell therapy, aiming to empower the full-cycle prevention and treatment of Alzheimer's disease through technological innovation. This investment does not require submission for approval by the company's board of directors or shareholders' meeting, does not constitute a related party transaction or a major asset reorganization, and is expected to have no significant impact on the company's performance in 2025